Exhibit 99.1

   MediCor Ltd. Appointments Two Members to Its Board of Directors

    LAS VEGAS--(BUSINESS WIRE)--Oct. 28, 2004--Las Vegas-based MediCor
Ltd. (OTCBB:MDCR) announced today the appointment of Thomas Y. Hartley
and Samuel Clay Rogers as independent directors. Additionally, Mr.
Hartley has agreed to serve as Chairman of the Audit Committee and Mr.
Rogers has agreed to serve as Chairman of the Compensation Committee.
The Board of Directors has designated Mr. Hartley as the financial
expert for the Audit Committee in accordance with the Sarbanes-Oxley
Act and the rules promulgated thereunder.
    Mr. Hartley, a certified public accountant, has over 40 years of
experience in public and private accounting, including having served
29 years with Deloitte Haskins & Sells (now Deloitte & Touche) as an
area managing partner. Mr. Rogers has more than 50 years of extensive
business experience, having served in various capacities, in both the
United States military and private sector businesses.
    According to MediCor Ltd. Chairman of the Board Mr. Donald K.
McGhan, "Mr. Hartley and Mr. Rogers bring both the breadth of
knowledge and years of experience that MediCor needs to support our
efforts to become the world leader in the area of aesthetic, plastic
and reconstructive surgery. With the elevated role and heightened
responsibility associated with serving on the board of a public
company, MediCor's management is honored these two men have chosen to
accept these board positions."

    About MediCor Ltd.

    MediCor acquires, develops, manufactures and markets products for
medical specialties in aesthetic, plastic and reconstructive surgery
and dermatology markets. Products include surgically implantable
prostheses for aesthetic, plastic and reconstructive surgery and scar
management products. Its products are sold worldwide to hospitals,
surgery centers and physicians through various distributors and direct
sales personnel. MediCor's strategy is to be the leading integrator of
selected international medical device markets, technologies and
corporations. To achieve this strategy, MediCor intends to build upon
and expand its business lines, primarily in the aesthetic, plastic and
reconstructive surgery and dermatology markets. MediCor intends to
accomplish this growth through the expansion of existing product lines
and offerings and through the acquisition of companies and other
assets, including intellectual property rights or distribution rights.

    CONTACT: MediCor Ltd., Las Vegas
             Marc S. Sperberg, 702-932-4568